Medical Devices US

US Colorectal Cancer Screening Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

US Colorectal Cancer Screening Market Industry Trends and Forecast to 2034: Segmented by (Test, Setting, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

US · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $3.80 Bn Placeholder estimate
Estimate 2025 $4.00 Bn 46.6% of the global market
Projected 2034 $6.43 Bn 60.5% Adds $2.42 Bn over 9 forecast years
CAGR 2025–2034 5.4% Faster than 39% of 180 Medical Devices markets here
Key players 6 +1
  • US is 46.64% of the global market.
  • In North America, the largest is US (this report) at $4.00 Bn.
  • Fastest growing: Canada at 6.9% a year.
  • US ranks 1st of 2 by size in North America.

Market size projection

US

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$2.42 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Colorectal Cancer Screening Market market size by year, US
YearMarket sizeChange that yearSince 2025
2024 (estimate) $3.80 Bn — —
2025 (base) $4.00 Bn +$205.2 Mn —
2026 (forecast) $4.22 Bn +$216.3 Mn +5.4%
2027 (forecast) $4.45 Bn +$227.9 Mn +11.1%
2028 (forecast) $4.69 Bn +$240.2 Mn +17.1%
2029 (forecast) $4.94 Bn +$253.2 Mn +23.4%
2030 (forecast) $5.21 Bn +$266.9 Mn +30.1%
2031 (forecast) $5.49 Bn +$281.3 Mn +37.1%
2032 (forecast) $5.79 Bn +$296.5 Mn +44.5%
2033 (forecast) $6.10 Bn +$312.5 Mn +52.3%
2034 (forecast) $6.43 Bn +$329.4 Mn +60.5%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

US Colorectal Cancer Screening Market Analysis at a glance
Market size, 2025$4.00 Bn placeholder estimate
Forecast, 2034$6.43 Bn placeholder estimate
Growth (CAGR), 2025–20345.4% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTest, setting and end user (see all)
Key playersExact Sciences Corporation, Guardant Health, Inc., Olympus Corporation, Quidel Corporation, Eiken Chemical and 1 more (see all)
Regulator in the USFDASource: US Food and Drug Administration. Checked 14 Nov 2026.
Active clinical trials76 in the USSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The US Colorectal Cancer Screening Market Analysis Executive Summary

Colorectal cancer screening finds bowel cancer and pre-cancer early, using stool tests, blood tests and colonoscopy.

Key segments of the colorectal Cancer Screening market include test (Stool DNA Tests, FIT Tests and Blood-Based Tests) and setting (At-Home, Clinics and Hospitals).

Bar chart: US Colorectal Cancer Screening market size, 2024–2034, placeholder estimates. $3.80 Bn in 2024, $4.00 Bn in 2025 and $6.43 Bn in 2034, 5.4% CAGR.
US Colorectal Cancer Screening market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

US Colorectal Cancer Screening Market Dynamics

Market Growth Drivers

Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the colorectal Cancer Screening market. Faster approvals and new combinations are improving survival.

Opportunity

Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the colorectal Cancer Screening market.

Market Restraints

High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the colorectal Cancer Screening market, especially in low- and middle-income countries.

Competitive Landscape for Colorectal Cancer Screening Market in the US

The colorectal Cancer Screening market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Colorectal Cancer Screening Market in the US

Colorectal Cancer Screening in the US: rules, payment and research

The FDA clears or approves medical devices by risk class, through 510(k) clearance, De Novo classification or premarket approval (PMA).⁠[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).⁠[2] ClinicalTrials.gov lists 76 studies on Colorectal Cancer Screening that are recruiting, active or about to start in the US.⁠[3]

[1] US Food and Drug Administration. Checked 14 Nov 2026.

[2] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how colorectal Cancer Screening products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in the US.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Colorectal Cancer Screening right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Colorectal Cancer Screening in context

The US compared

  • Health spending per person: 13,473 US$ per person (2023). World: 1,317 US$ per person (2023).[1]
  • Doctors: 3.68 per 1,000 people (2022). World: 1.86 per 1,000 people (2022).[2]
  • People aged 65 and over: 18.4% of people (2025). World: 10.4% of people (2025).[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 19 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 19 Nov 2026.

Free data on this topic

Inside the US

Quick answers

Frequently asked questions

How big is the Colorectal Cancer Screening market in the US?
Placeholder estimate: about $4.00 Bn in 2025, rising to about $6.43 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Colorectal Cancer Screening market in the US growing?
Placeholder estimate: about 5.4% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Colorectal Cancer Screening market report cover?
The report splits the market by test (Stool DNA Tests, FIT Tests, Blood-Based Tests, Colonoscopy and more), setting (At-Home, Clinics, Hospitals) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Colorectal Cancer Screening market?
Key players include Exact Sciences Corporation, Guardant Health, Inc., Olympus Corporation, Quidel Corporation, Eiken Chemical and FUJIFILM Holdings Corporation.
What is driving the Colorectal Cancer Screening market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the colorectal Cancer Screening market. Faster approvals and new combinations are improving survival.
Who regulates Colorectal Cancer Screening in the US?
The FDA clears or approves medical devices by risk class, through 510(k) clearance, De Novo classification or premarket approval (PMA). Source: US Food and Drug Administration. Checked 14 Nov 2026.
How is healthcare paid for in the US?
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS). Source: Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
How many clinical trials on Colorectal Cancer Screening are running in the US?
76 studies are recruiting, active or about to start in the US, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
How much research is published on Colorectal Cancer Screening?
PubMed lists 3,251 papers on Colorectal Cancer Screening added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Medical Devices reports in US

See all

Related on oncology and diagnostics and lab testing

See the topic